
    
      Consenting participants will be screened and within 14 days randomly allocated to receive
      either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants
      will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the
      week 12 visit, patients will not be dispensed any study treatment. In phase 2 all study
      treatment will stop for 6 weeks. At week 18 patients will be seen for a final study visit.
    
  